SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities, alleging that the company made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit claims that defendants overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the Rosen Law Firm's website or contacting their office directly [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].